<DOC>
	<DOCNO>NCT00970268</DOCNO>
	<brief_summary>The purpose extension study evaluate long-term safety , tolerability , efficacy inhale aclidinium bromide two dose level patient moderate severe chronic obstructive pulmonary disease ( COPD ) . This study 54 week duration ; 52-week double-blind treatment period 2 week follow-up phone call , follow 12 week lead-in study . All patient randomize lead-in study one two dos aclidinium .</brief_summary>
	<brief_title>Long-term Extension Study Safety , Tolerability , Efficacy Aclidinium Bromide Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD ) ( LAS-MD-36 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Completion leadin study ( NCT00891462 ) Use anticipate use medication prohibit study Evidence abnormal clinical laboratory value , vital sign , electrocardiographic ( ECG ) result presence abnormities physical examination find The presence anticholinergic effect ( eg , dry mouth , urinary retention , narrow angle glaucoma ) QTcB &gt; 500 msec predose postdose ECG Women pregnant , intend become pregnant , breastfeed A life expectancy le 1 year Noncompliance IP dose and/or attend clinic visit leadin study Significant interruption doubleblind therapy transition leadin study extension study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
</DOC>